Subscribe To
CTXR / Citius (CTXR) Posts Top-Line Data From Pivotal Lymphoma Study
CTXR News
By Seeking Alpha
June 2, 2023
Citius Pharmaceuticals: Steer Clear From This One
The article provides an updated analysis of Citius Pharmaceuticals following a previous piece in February 2023. Citius' lead therapy has a midsummer 2 more_horizontal
By PRNewsWire
January 11, 2023
Citius Pharmaceuticals to Present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023
CRANFORD, N.J. , Jan. 11, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical more_horizontal
By Seeking Alpha
November 8, 2022
Citius Pharmaceuticals: Large Price Action Imminent From Catalysts Within 60 Days
Citius Pharmaceuticals, Inc. has a handful of catalysts set to occur in the next few months. Of these, some are critical to extending its cash runway more_horizontal
By Seeking Alpha
July 5, 2022
Citius Pharmaceuticals: Hoping For A Turnaround Strategy
Citius Pharmaceuticals is yet to release test results a year after it was granted positive recommendation by the Independent Data Monitoring Committee more_horizontal
By PRNewsWire
April 14, 2022
Citius Pharmaceuticals to Present at the NobleCon18 Investor Conference on April 20, 2022
CRANFORD, N.J. , April 14, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutica more_horizontal
By Zacks Investment Research
April 7, 2022
Citius (CTXR) Posts Top-Line Data From Pivotal Lymphoma Study
Citius (CTXR) releases encouraging top-line data from the phase III study on I/ONTAK for the treatment of persistent or recurrent cutaneous T-cell lym more_horizontal
By Market Watch
April 6, 2022
Shares of Citius jump 18% on new data for experimental lymphoma drug
Shares of Citius Pharmaceuticals Inc. CTXR, -1.60% were up 18.5% in premarket trading on Wednesday after the company shared positive topline data from more_horizontal
By Seeking Alpha
March 28, 2022